First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study.

Date publication

juin 2025

Journal

Head & neck

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel , Pr PEIFFERT Didier , Pr GALLET Patrice , Dr LAMBERT Aurélien

Tous les auteurs :
Simon A, Abdeddaim C, Nguyen D, Gallet P, Peiffert D, Lambert A, Geoffrois L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40491285

Résumé

In Europe, pembrolizumab with or without chemotherapy is the recommended first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1. These regimens were studied in selected populations, which may not reflect real-world patients.

Mots clés

R/M HNSCC, first‐line, head and neck cancer, immunotherapy, real‐world

Référence

Head Neck. 2025 06 10;: